-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
RP is an inflammatory disease that affects tissue around the heart and affects 15% to 30% of patients with acute pericaritisPatients with the disease have repeated chest pain attacks, accompanied by life-threatening complications that severely limit the patient's physical activity and daily lifeCurrently, standard therapies are nonsteroidal anti-inflammatory drugs (NSAIDs), aphasia, and corticosteroids (CS), and long-term use of these drugs can cause safety problems for patients, especially CS drugsLeukin-1 (IL-1) is one of the cytokines of the pathophysiology of the disease, and tissue damage caused by IL-1 alpha and IL-1 beta in the heart bag is stimulated by the secretion of additional IL-1 alpha and IL-1 beta, thus causing the continuation of the inflammation of the heart bagil-1-mediated inflammation of RP disease (Photo: Kiniksa website)Rilonacept is a soluble fusion protein injected by subcutaneous injections, with the ligand binding domain of the extracellular part of IL-1 receptor 1 (IL-1R1), and il-1 receptor-assisted protein (IL-1RAcP), linearly connected to the Fc binding domain of the human immunoglobulin G1 (IgG1)It suppresses IL-1 signaling by acting as a receptor that binds to IL-1 alpha and IL-1 beta, thus blocking their interaction with the IL-1 receptor on the cell surfaceRilonacept was discovered and developed by Regeneron, and Kiniksa further developed treatments for RP patients with its exclusive permissionPreviously, The regenerative yuan company has been named Arcalyst as a commodity rilonacept was approved for use in the United States to treat cold-related periodic syndrome (CAPS)the composition and structure of the rilonacept (Photo: Kiniksa website)the determination of the breakthrough therapy is based on positive results obtained by rilonacept in a Phase 2 clinical trialThe results showed that during the six-month treatment period, the incidence of heart encased in patients treated with rilonacept decreased from 3.9 times per year to less than 0.18 per year compared to the patient's natural historyIn addition, rilonacept enables rapid improvement in the clinical performance of cardioclonitis in RP patients with pain-related quality of life (QoL), as well as C-reactive protein (CRP) levels, cardiac fluid, and changes in heart activityin subgroups of patients with CS drug dependence, patients received rilonacept treatment without recurrence of pertthanitis, and during this period were not treated with CS drugsThe positive data from this trial supports Kiniksa's continuation of the key Phase 3 clinical trial of rilonacept treatment RP" data from the Phase 2 trial show edgtospt can also reduce the recurrence of patributitis in RP patients while reducing or stopping CS drug useRilonacept has the potential to meet this highly unmet treatment need and improve patients' living conditions," said Sanj KPatel, Chief Executive Officer of Kiniksa and Chairman of the Board of DirectorsReferences:smouldering The Sessions for Rilonacept for The Treatment of Recurrent Pericarditis, Retrieved November 20, 2019, from https://
Efficacy and Safety of Rilonacept in Recurrent Pericarditis: A Multicenter Phase 2 Clinical Trial, November 20, 2019, from https://investors.kiniksa.com/static-files/ade7c9af-8b84-4c7a-a29d-3b1c254d1fd8original title: Courier - Reduce the number of heartattack episodes 20 times! IL-1 inhibitors identified by FDA breakthrough therapy